Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.00
Bid: 63.00
Ask: 67.00
Change: -0.50 (-0.76%)
Spread: 4.00 (6.349%)
Open: 65.50
High: 65.50
Low: 65.00
Prev. Close: 65.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

7 Jul 2005 07:01

Torex Retail PLC07 July 2005 7 July 2005 Torex Retail Plc Trading Update Torex Retail Plc ("Torex Retail" or "the Group"), is pleased to announce apositive update on trading for the six months ended 30 June 2005. This reflects a strong organic performance in all areas of the Group, includingnew LUCAS contract wins totalling approximately £10 million. LUCAS • New sales success for LUCAS, the Group's market leading JAVA based electronic point of sale (EPOS) solution, with a number of significant contract wins with major international retailers including Deichmann, Reiss and Esprit and UK based retailers including RD Scott, Co-op Home Stores and Mitsukoshi. In addition, LUCAS has now been installed in over 40 stores and more than 150 lanes in the UK and Ireland, with more planned for the next few months. These installations will now act as excellent reference sites for our large prospect pipeline. PERFORMANCE MANAGEMENT PRODUCTS • Significant new wins for SMARTDECISION, the Group's merchandise planning product, including Ann Taylor in America, Modelo Continente in Portugal (part of the €1.6 billion turnover Sonnae Group) and Littlewoods and Oldrids in the UK. PETROLEUM & CONVENIENCE • A new £3.3 million contract for the Petroleum and Conveniencedivision, to install its market leading PoS solution 'Iridium' and backoffice system 'Prism' into 225 stores across the UK. BUSINESS DEVELOPMENT Alphameric Retail, which was acquired in November 2004, is now fully integratedinto Torex Retail, ahead of schedule. Through RSS, which was acquired in May 2005, we are achieving real momentum andare already making strong progress in gaining greater penetration of the USmarket, the largest market in the world for retail systems. In addition, we are currently working towards finalising the recommended offersfor XN Checkout Holdings plc and Anker plc. Both of these businesses meet withour strategic goal of ultimately becoming a global market leader and inparticular are expected to be earnings enhancing. This statement regardingearnings enhancement does not constitute a profit forecast nor should it beinterpreted to mean that earnings per share of Torex Retail for the current orfuture years will necessarily match or exceed the historical published earningsper share of Torex Retail. INTERIM RESULTS The Board intends to announce results for the six months ended 30 June 2005 inlate September and expects these results to be consistent with full yearmanagement expectations. The Group continues to enjoy a high level of revenuevisibility, based on strong recurring revenues from its blue-chip customer base.This, coupled with its new business pipeline, gives the directors confidenceabout the Group's prospects for 2005 and beyond. Chris Moore, Chief Executive, Torex Retail Plc, comments: "I am delighted with the progress we have made in all areas of our operationsduring the first half of this year. The cyclical upturn in the market is nowgathering momentum, most notably evidenced by our significant new contract winsfor LUCAS. Coupled with this, our accelerated growth plan through acquisitionsis already positioning us such that we are currently in discussions with some ofthe world's largest retailers as potential customers, both in Europe and theUSA. Enquiries: Torex Retail Plc 0870 050 9900 Chris Moore, Chief Executive Richard Thompson, Group Finance Director Citigate Dewe Rogerson 020 7638 9571 Ginny Pulbrook / Seb Hoyle This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.